What is the 13F Pro Quality Score for ESPR?

13F Pro ranks Esperion Therapeutics, Inc. (ESPR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ESPR's current score at https://13fpro.ai/company/ESPR (free sign-up required for the full ranking).

Which hedge funds own the most ESPR stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ESPR include BlackRock,, WASATCH ADVISORS, Two Seas Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ESPR as soon as new 13F filings post.

Where does 13F Pro source ESPR data?

All Esperion Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Esperion Therapeutics, Inc. files with the SEC under CIK 1434868. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ESPR in?

Esperion Therapeutics, Inc. (ESPR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ESPR research updated on 13F Pro?

ESPR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Esperion Therapeutics, Inc.(ESPR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1434868 ESPR stock profile & AI dashboard →

13F Pro Quality Score

46.3/100

Rank #1,835 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

89.6/100

Profitability

43.8/100

Balance Sheet

28.8/100

Earnings Quality

1.3/100

Free Cash Flow

20.8/100

Institutional Flow

92.5/100

Revenue Scale

34.0/100

Dilution Risk

36.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ESPR Scores 44/100

exact factor attribution · 2026-08-29

ESPR's composite is driven by revenue growth and institutional flow, held back by earnings quality and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.4 pts

92th pct

Institutional flow

+1.3 pts

76th pct

▲2

Shareholder dilution

-0.7 pts

37th pct

Earnings growth

-1.0 pts

30th pct

Profitability

-1.0 pts

43th pct

Scale

-1.8 pts

38th pct

Capital efficiency

-2.0 pts

30th pct

Free cash flow

-4.5 pts

20th pct

Earnings quality

-4.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ESPR Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for Esperion Therapeutics, Inc. (ESPR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ESPR at 46.3/100 on a 32-signal composite quality model, placing it at rank #1,835 of 2,960 stocks — the bottom half of the AI-ranked universe. ESPR scores in the top quartile across institutional flow (92.5), revenue growth (89.6). Areas of concern include earnings quality (1.3) and free cash flow (20.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 36.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Esperion Therapeutics, Inc. reports quarterly revenue of $80.1M, net income of $-25.2M, free cash flow of $-27.9M. Top institutional holders of ESPR by reported 13-F value include BlackRock, WASATCH ADVISORS, Two Seas Capital, based on the most recent SEC filings. ESPR trades on the Nasdaq exchange and files with the SEC under CIK 1434868. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ESPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Esperion Therapeutics, Inc. directly from SEC EDGAR. Esperion Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 46 since 2021, currently 46.3 — an improving long-term trajectory across 67 quarterly and live scoring snapshots.

✦

Fun facts about Esperion Therapeutics, Inc.

Quirks, history, and lore behind ESPR — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Michigan.
2
The Numbers
Revenue is in the tens of millions of dollars annually — this is a company still climbing the commercial ladder, not printing blockbuster profits yet.
3
The History
Founded in the early 2000s, it spent years in clinical development before finally winning FDA approval for its lead drug in the cholesterol space.
4
The Secret
Its drugs target LDL cholesterol through a mechanism distinct from statins — specifically aimed at patients who can't tolerate statins or need additional lowering.
5
The Lore
Its approved oral therapy bempedoic acid works by inhibiting an enzyme upstream in the cholesterol synthesis pathway — clever enough to turn heads in cardiology circles.
6
The Giveaway
The maker of Nexletol and Nexlizet — oral, non-statin cholesterol pills — this Ann Arbor biotech's ticker is almost as optimistic as its pipeline.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$80.1M

Net Income

Q1 2026

$-25.2M

Free Cash Flow

Q1 2026

$-27.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+21.3% YoY

$403.1MFY 2025

FY22 $75.5MFY23 $116.3MFY24 $332.3MFY25 $403.1M

Net Income

+56.2% YoY

$-22.7MFY 2025

FY22 $-233.7MFY23 $-209.2MFY24 $-51.7MFY25 $-22.7M

Operating Income

+10.8% YoY

$60.3MFY 2025

FY22 $-179.5MFY23 $-155.6MFY24 $54.4MFY25 $60.3M

EPS (Diluted)

+60.7% YoY

$-0.11FY 2025

FY22 $-3.52FY23 $-2.03FY24 $-0.28FY25 $-0.11

Total Assets

+35.5% YoY

$465.9MFY 2025

FY22 $247.9MFY23 $205.8MFY24 $343.8MFY25 $465.9M

Op. Cash Flow

+44.6% YoY

$-13.1MFY 2025

FY22 $-174.8MFY23 $-135.5MFY24 $-23.7MFY25 $-13.1M

Free Cash Flow

+45.4% YoY

$-13.1MFY 2025

FY22 $-174.8MFY23 $-135.5MFY24 $-24.0MFY25 $-13.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$403.1M +21.3%	$332.3M +185.7%	$116.3M +54.1%	$75.5M -3.8%	$78.4M -65.5%	$227.5M
Net Income	$-22.7M +56.2%	$-51.7M +75.3%	$-209.2M +10.4%	$-233.7M +13.2%	$-269.1M -87.5%	$-143.6M
Operating Income	$60.3M +10.8%	$54.4M +135.0%	$-155.6M +13.3%	$-179.5M +20.8%	$-226.7M -86.8%	$-121.4M
EPS (Diluted)	$-0.11 +60.7%	$-0.28 +86.2%	$-2.03 +42.3%	$-3.52 +62.2%	$-9.31 -78.0%	$-5.23
Total Assets	$465.9M +35.5%	$343.8M +67.1%	$205.8M -17.0%	$247.9M -35.0%	$381.6M +8.0%	$353.3M
Operating Cash Flow	$-13.1M +44.6%	$-23.7M +82.5%	$-135.5M +22.5%	$-174.8M +33.7%	$-263.8M -209.7%	$-85.2M
Free Cash Flow	$-13.1M +45.4%	$-24.0M +82.3%	$-135.5M +22.5%	$-174.8M +33.7%	$-263.8M -206.6%	$-86.0M

Get alerted when ESPR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Esperion Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ESPR

BlackRock, Inc.
$48.9M17,852,427 sh
WASATCH ADVISORS LP
$43.2M15,768,897 sh
Two Seas Capital LP
$31.2M11,394,833 sh
ORBIMED ADVISORS LLC
$29.0M10,570,300 sh
VANGUARD CAPITAL MANAGEMENT LLC
$28.6M10,433,760 sh
TWO SIGMA INVESTMENTS, LP
$25.9M9,458,779 sh
MARSHALL WACE, LLP
$19.4M7,075,083 sh
STATE STREET CORP
$19.3M7,055,794 sh
D. E. Shaw & Co., Inc.
$17.9M6,540,785 sh
GEODE CAPITAL MANAGEMENT, LLC
$16.3M5,955,739 sh

Fund	Value	Shares
BlackRock, Inc.	$48.9M	17,852,427
WASATCH ADVISORS LP	$43.2M	15,768,897
Two Seas Capital LP	$31.2M	11,394,833
ORBIMED ADVISORS LLC	$29.0M	10,570,300
VANGUARD CAPITAL MANAGEMENT LLC	$28.6M	10,433,760
TWO SIGMA INVESTMENTS, LP	$25.9M	9,458,779
MARSHALL WACE, LLP	$19.4M	7,075,083
STATE STREET CORP	$19.3M	7,055,794
D. E. Shaw & Co., Inc.	$17.9M	6,540,785
GEODE CAPITAL MANAGEMENT, LLC	$16.3M	5,955,739

Companies Similar to ESPR

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

AVNS

AVANOS MEDICAL, INC.

AI score

Very similar · 26 shared holders

AQR Arbitrage LLC NEXPOINT ASSET MANAGEMENT, L.P.TIG Advisors, LLC

TALK

Talkspace, Inc.

AI score

Shared smart-money ownership · 23 shared holders

AQR Arbitrage LLC NEXPOINT ASSET MANAGEMENT, L.P.Sagefield Capital LP

ANAB

ANAPTYSBIO, INC

AI score

Similar quality profile · 5 shared holders

Voleon Capital Management LP Rangeley Capital, LLC China Universal Asset Management Co., Ltd.

SLAB

SILICON LABORATORIES INC.

AI score

Similar quality profile · 20 shared holders

AQR Arbitrage LLC TIG Advisors, LLC GABELLI & Co INVESTMENT ADVISERS, INC.

ADPT

Adaptive Biotechnologies Corp

AI score

Similar quality profile · 6 shared holders

WASATCH ADVISORS LP Polar Asset Management Partners Inc.Voleon Capital Management LP

SEM

SELECT MEDICAL HOLDINGS CORP

AI score

Similar quality profile · 18 shared holders

GLAZER CAPITAL, LLC AQR Arbitrage LLC ODDO BHF ASSET MANAGEMENT SAS

OGN

Organon & Co.

AI score

Similar quality profile · 27 shared holders

GLAZER CAPITAL, LLC AQR Arbitrage LLC NEXPOINT ASSET MANAGEMENT, L.P.

SUPN

SUPERNUS PHARMACEUTICALS, INC.

AI score

Similar quality profile · 4 shared holders

HARVEST MANAGEMENT LLC China Universal Asset Management Co., Ltd.GF FUND MANAGEMENT CO. LTD.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ESPR on your watchlist

Track score changes the day Esperion Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ESPR a good stock to buy?

13F Pro's AI-powered analysis of Esperion Therapeutics, Inc. (ESPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ESPR are available on the ESPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ESPR is classified as a small company.

Which hedge funds own ESPR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ESPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Esperion Therapeutics, Inc.'s investment landscape.